Granulocyte transfusions in children and adults with hematological malignancies: benefits and controversies. 2015

Chiara Cugno, and Sara Deola, and Perla Filippini, and David F Stroncek, and Sergio Rutella
Division of Translational Medicine, Clinical Research Center, Sidra Medical and Research Center, Out-Patient Clinic, Al Luqta Street, Education City North Campus, P.O. Box 26999, Doha, Qatar. ccugno@sidra.org.

Bacterial and fungal infections continue to pose a major clinical challenge in patients with prolonged severe neutropenia after chemotherapy or hematopoietic stem cell transplantation (HSCT). With the advent of granulocyte colony-stimulating factor (G-CSF) to mobilize neutrophils in healthy donors, granulocyte transfusions have been broadly used to prevent and/or treat life-threatening infections in patients with severe febrile neutropenia and/or neutrophil dysfunction. Although the results of randomized controlled trials are inconclusive, there are suggestions from pilot and retrospective studies that granulocyte transfusions may benefit selected categories of patients. We will critically appraise the evidence related to the use of therapeutic granulocyte transfusions in children and adults, highlighting current controversies in the field and discussing complementary approaches to modulate phagocyte function in the host.

UI MeSH Term Description Entries
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D006098 Granulocytes Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS. Granulocyte
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine
D016913 Blood Component Transfusion The transfer of blood components such as erythrocytes, leukocytes, platelets, and plasma from a donor to a recipient or back to the donor. This process differs from the procedures undertaken in PLASMAPHERESIS and types of CYTAPHERESIS; (PLATELETPHERESIS and LEUKAPHERESIS) where, following the removal of plasma or the specific cell components, the remainder is transfused back to the donor. Blood Component Transfusions,Component Transfusion, Blood,Component Transfusions, Blood,Transfusion, Blood Component,Transfusions, Blood Component
D019337 Hematologic Neoplasms Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES. Blood Cancer,Hematologic Malignancies,Hematopoietic Neoplasms,Hematologic Malignancy,Hematological Malignancies,Hematological Neoplasms,Hematopoietic Malignancies,Malignancies, Hematologic,Malignancy, Hematologic,Neoplasms, Hematologic,Neoplasms, Hematopoietic,Blood Cancers,Cancer, Blood,Hematologic Neoplasm,Hematological Malignancy,Hematological Neoplasm,Hematopoietic Malignancy,Hematopoietic Neoplasm,Malignancy, Hematological,Malignancy, Hematopoietic,Neoplasm, Hematologic,Neoplasm, Hematological,Neoplasm, Hematopoietic

Related Publications

Chiara Cugno, and Sara Deola, and Perla Filippini, and David F Stroncek, and Sergio Rutella
January 1979, Medical and pediatric oncology,
Chiara Cugno, and Sara Deola, and Perla Filippini, and David F Stroncek, and Sergio Rutella
July 2006, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,
Chiara Cugno, and Sara Deola, and Perla Filippini, and David F Stroncek, and Sergio Rutella
February 1981, European journal of pediatrics,
Chiara Cugno, and Sara Deola, and Perla Filippini, and David F Stroncek, and Sergio Rutella
March 2009, Journal of pediatric hematology/oncology,
Chiara Cugno, and Sara Deola, and Perla Filippini, and David F Stroncek, and Sergio Rutella
January 1996, Journal of palliative care,
Chiara Cugno, and Sara Deola, and Perla Filippini, and David F Stroncek, and Sergio Rutella
January 2016, PloS one,
Chiara Cugno, and Sara Deola, and Perla Filippini, and David F Stroncek, and Sergio Rutella
August 2014, Pediatric hematology and oncology,
Chiara Cugno, and Sara Deola, and Perla Filippini, and David F Stroncek, and Sergio Rutella
July 2022, International journal of molecular sciences,
Chiara Cugno, and Sara Deola, and Perla Filippini, and David F Stroncek, and Sergio Rutella
December 2018, Deutsches Arzteblatt international,
Chiara Cugno, and Sara Deola, and Perla Filippini, and David F Stroncek, and Sergio Rutella
March 2011, Expert review of anti-infective therapy,
Copied contents to your clipboard!